ArticleBiometrics2018
A multi-source adaptive platform design for testing sequential combinatorial therapeutic strategies.
Article in Biometrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- Challenges, opportunities, and innovative statistical designs for precision oncology trials.Annals of translational medicine · 2022Trial
- A group-sequential randomized trial design utilizing supplemental trial data.Statistics in medicine · 2022Trial
- Randomization in the age of platform trials: unexplored challenges and some potential solutions.BMC medical research methodology · 2025Review
- Master Protocol Design With Hybrid Control for Efficient Early-Phase Trial Consolidation.JCO precision oncology · 2025Article
- Dualistic Dynamics in Neuropsychiatry: From Monoaminergic Modulators to Multiscale Biomarker Maps.Biomedicines · 2025Article
- Reinforced Borrowing Framework: Leveraging Auxiliary Data for Individualized Inference.Statistics in medicine · 2024Article
- Semi-supervised mixture multi-source exchangeability model for leveraging real-world data in clinical trials.Biostatistics (Oxford, England) · 2024Article
- A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.Statistics in medicine · 2024Article
- A practical guide to adopting Bayesian analyses in clinical research.Journal of clinical and translational science · 2024Article
- Treatment Comparisons in Adaptive Platform Trials Adjusting for Temporal Drift.Statistics in biopharmaceutical research · 2024Article
- Improved efficiency for cross-arm comparisons via platform designs.Biostatistics (Oxford, England) · 2023Article
- Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity.Biometrics · 2023Article
- Dynamic use of historical controls in clinical trials for rare disease research: A re-evaluation of the MILES trial.Clinical trials (London, England) · 2023Article
- Recent innovations in adaptive trial designs: A review of design opportunities in translational research.Journal of clinical and translational science · 2023Review
- Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts.JCO precision oncology · 2022Article
- Article
- BRIDGING RANDOMIZED CONTROLLED TRIALS AND SINGLE-ARM TRIALS USING COMMENSURATE PRIORS IN ARM-BASED NETWORK META-ANALYSIS.The annals of applied statistics · 2021Article
- Calibrated dynamic borrowing using capping priors.Journal of biopharmaceutical statistics · 2021Article
- Physical therapy for the treatment of respiratory issues using Systemic Manual Therapy protocols.Journal of bodywork and movement therapies · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Traditional paradigms for clinical translation are challenged in settings where multiple contemporaneous therapeutic strategies have been identified as potentially beneficial. Platform trials have emerged as an approach for sequentially comparing multiple trials using a single protocol. The Ebola virus disease outbreak in West Africa represents one recent example which utilized a platform design. Specifically, the PREVAIL II master protocol sequentially tested new combinations of therapies against the concurrent, optimal standard of care (oSOC) strategy. Once a treatment demonstrated sufficient evidence of benefit, the treatment was added to the oSOC for all future comparisons (denoted as segments throughout the manuscript). In the interest of avoiding bias stemming from population drift, PREVAIL II considered only within-segment comparisons between the oSOC and novel treatments and failed to leverage data from oSOC patients in prior segments. This article describes adaptive design methodology aimed at boosting statistical power through Bayesian modeling and adaptive randomization. Specifically, the design uses multi-source exchangeability models to combine data from multiple segments and adaptive randomization to achieve information balance within a segment. When compared to the PREVAIL II design, we demonstrate that our proposed adaptive platform design improves power by as much as 51% with limited type-I error inflation. Further, the adaptive platform effectuates more balance with respect to the distribution of acquired information among study arms, with more patients randomized to experimental regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.